Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25 / - 13 mm Hg (systolic / diastolic, p<0.0001 / p=0.0035)
- Blood pressure reduction dependent on vaccine dose and induced antiangiotensin II antibody levels
- Detailed results presented today at the Seventeenth European Meeting on Hypertension in Milan, Italy

SCHLIEREN (Zurich), Switzerland and MILAN, Italy, June 17, 2007 - Cytos Biotechnology AG (SWX:CYTN) presented today new clinical data on its hypertension vaccine CYT006-AngQb at the Seventeenth European Meeting on Hypertension in Milan, Italy. The vaccine candidate was tested in a placebocontrolled, double-blind phase IIa clinical trial in 72 patients with mild to moderate hypertension.

On January 26, 2007, Cytos Biotechnology reported top-line data from this study, which showed that the 300 ?g dose of the vaccine was safe, very well tolerated and efficacious in lowering day-time ambulatory blood pressure. The new data presented today show a particularly strong efficacy of the vaccine in early morning hours, a critical time period when serious cardiovascular events frequently occur. The graph below shows the mean ambulatory blood pressure during the 24-hour measurement period 14 weeks after the first injection of the vaccine or of placebo. The early morning rise of blood pressure starting at 5 am was significantly suppressed by the vaccine, leading at 8 am to a change from baseline of the blood pressure of - 25 / - 13 mm Hg compared to placebo (SBP / DBP, p<0.0001 / p=0.0035).


*SEE ATTACHMENT FOR FIGURE*

The strong suppression of the early morning rise of blood pressure was associated with an exceptionally low increase in plasma renin concentration (PRC) from a mean renin concentration of 5.1 pg/ml at baseline to 6.3 pg/ml at week 14 (p=0.02). Inhibition of the renin-angiotensin system by small molecule drugs is known to induce a reactive rise of the plasma renin concentrati
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:10/31/2014)... 2014  Semler Scientific, Inc. (Nasdaq: ... company that develops patented products that assist healthcare ... today reported financial results for the third quarter ... "In the third quarter of 2014, ... M.D., chief executive officer of Semler.  "We moved ...
(Date:10/31/2014)... , Oct. 31, 2014  Australian biopharmaceutical company Specialised ... (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will ... patients with metastatic pancreatic cancer from 1 November. ... cancer is the 5 th most common cause ... all cancer deaths, with the lowest 5-year survival of ...
(Date:10/31/2014)... -- Investor-Edge has initiated coverage on the ... Isis Pharmaceuticals Inc. (NASDAQ: ISIS ), Halozyme ... Inc. (NASDAQ: ACAD ), and Synta Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,566.14, up 0.37%, the Dow Jones Industrial Average ...
Breaking Medicine Technology:Semler Reports Third Quarter 2014 Financial Results 2Semler Reports Third Quarter 2014 Financial Results 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5
... Reportlinker.com announces that a new market research ... Global Intraocular Lenses Industry ... the worldwide markets for Intraocular Lenses in US$ ... Lenses, and Foldable Intraocular Lenses. The report provides ...
... New Mexico Software, Inc. (OTC Bulletin ... and solutions that enable improved and faster communication within the healthcare ... diagnostic imaging services for the Heart Institute of the Caribbean ... Jamaica. HIC is now sending nuclear and other exams ...
Cached Medicine Technology:Reportlinker Adds Global Intraocular Lenses Industry 2New Mexico Software Launches Company's First International Telemedicine Service 2New Mexico Software Launches Company's First International Telemedicine Service 3
(Date:10/31/2014)... 2014 Uniwigs.com newly arrived flip in ... model can comfortably attach itself around people’s heads with a ... generation of flip-in extensions comes with adjustable loops, which are ... part and customers can now adjust the wire to best ... people apply this new generation of flip ins, they simply ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Med-Care Diabetic ... on the highest principles of patient care and service, ... leading health and wellness website, to provide an online ... diabetes. , The Diabetes Health Center will provide ... for those living with diabetes. Content will feature advice ...
(Date:10/31/2014)... 2014 (HealthDay News) -- A few simple steps can help ... sleep expert says. "Adjusting to the end of Daylight ... handling the time change in the spring. The main reason ... fall time change," Dr. Praveen Rudraraju, director of the Center ... N.Y., said in a hospital news release. The many ...
(Date:10/31/2014)... By Dennis Thompson ... -- The World Bank pledged Thursday an additional $100 million ... West Africa. The money, which brings the World Bank,s ... to attract more foreign health care workers to the three ... "The world,s response to the Ebola crisis has increased significantly ...
(Date:10/31/2014)... to generic hormone therapy medicines improves the chances that ... a new study found. "We know that hormone ... reduce recurrence by up to 50 percent," study leader ... Columbia University Medical Center in New York City, said ... by our group and others has shown that a ...
Breaking Medicine News(10 mins):Health News:UniWigs Unveiles New Generation of Flip In Hair Extensions 2Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 2Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 3Health News:Make the Most of This Weekend's Time Change 2Health News:World Bank Pledges $100M More to Fight West Africa's Ebola Outbreak 2Health News:Generic Drugs May Help Breast Cancer Patients Stick to Therapy 2
... FLORHAM PARK, N.J., Jan. 6 Managed Health Care ... Butterfield, RN, has joined MHA, Inc. as the new ... newly created role Pegeen will have executive responsibility for ... Michael J. Sicilian, President of MHA, commented, "The creation ...
... Web-Based Community for Parents of Children with DisabilitiesNEWTON, ... community for parents of disabled children, today announced ... to assist parents of children with disabilities, the ... resource library for families. ChildRC ( www.ChildRC.com ) ...
... Inc. (TSX: IM) ("IMRIS" or the "Company") today ... Australia for its IMRISneuro surgical imaging solution, thereby ... Canberra Hospital has chosen a two-room configuration of ... a larger Australian Capital Territory infrastructure project. , ...
... Jan. 6, 2009 The Procter & Gamble Company,(NYSE: ... have reached a settlement in the lawsuit P&G,filed on ... trade dress and,patent infringement on its Olay Regenerist brands. ... Fruit of the Earth recognized the validity of,P&G,s rights ...
... means condition could be biologically driven, researchers say , , ... traumatized by sexual, physical or psychological abuse are more ... research suggests. , The study also states that ... be based in biology. The reason: There appears to ...
... PET Infusion System to Compare Techniques for Patient ... signed a research agreement with the University of ... MEDRAD Intego(TM) PET Infusion System. The researchers ... control the radioactive dose delivered during PET imaging ...
Cached Medicine News:Health News:MHA Announces Pegeen Butterfield, RN as Senior Vice President of Trade Relations 2Health News:ChildRC.com Launches The Child Resource Center 2Health News:Childhood Trauma Tied to Chronic Fatigue Syndrome 2Health News:Childhood Trauma Tied to Chronic Fatigue Syndrome 3Health News:MEDRAD Sponsors PET Research with University of Zurich 2Health News:MEDRAD Sponsors PET Research with University of Zurich 3Health News:MEDRAD Sponsors PET Research with University of Zurich 4
The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s...
The Concept Plus also allows users to transfer large bottles, flasks and other equipment, quickly and efficiently. The front-loading interlock features class leading one touch operation and easy acce...
Providing a perfect combination of capacity, speed and innovation, the Concept 400 delivers simple sophistication and new levels of comfort and convenience....
Lose the variability of anaerobic jars and step into the 21st century with the anaerobic workstation that provides the answer to the common problems associated with anaerobic microbiology....
Medicine Products: